France Offers Updated Protein-based COVID-19 Vaccine in Hospitals and Pharmacies

Novavax Inc. announced today that its updated protein-based COVID-19 vaccine is now available in France to prevent COVID-19 in individuals aged 12 and older.

As of December 19, 2023, the updated XBB version of its Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601), is intended for adults and adolescents aged 12 and over, regardless of their vaccination history, but is not recommended for pregnant women pending further data, according to the National recommendation of France's General Directorate of Health.

France's Ministry of Health provides the new protein-based vaccine in hospitals (December 7, 2023) and retail pharmacies (December 14, 2023).

As outlined in French vaccination recommendations, 'a diverse vaccine portfolio with both mRNA and non-mRNA options is critical to helping to protect communities across France against COVID-19 this vaccination season and in future.'

In the United States,  the Food and Drug Administration amended the EUA on October 3, 2023, of the Novavax COVID-19 Vaccine, Adjuvanted, for use in individuals 12 and older, to include the 2023-2024 formula. 

As of December 19, 2023, Novavax's protein-based vaccine is the only non-mRNA COVID-19 vaccine available in the U.S.